Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03415126 · ClinicalTrials.gov registry record · Phase 1
A Study of ASN007 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Asana BioSciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03415126 is a Phase 1 study that has completed, run by Asana BioSciences. The registered enrollment target is 49 participants.
The verdict
NCT03415126, a Phase 1 study, has completed, sponsored by Asana BioSciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.
Interventions
- DRUG ASN007: ascending doses
- DRUG ASN007 RD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03415126
The ClinicalTrials.gov registry entry for NCT03415126 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Asana BioSciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ASN007: ascending doses is the first listed.
NCT03415126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03415126 about?
NCT03415126 is a clinical study titled "A Study of ASN007 in Patients With Advanced Solid Tumors". The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.
What is the current status of trial NCT03415126?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-01-19. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT03415126?
The interventions under investigation include: ASN007: ascending doses (DRUG), ASN007 RD (DRUG).
Who is sponsoring clinical trial NCT03415126?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.